SION 10-Q filed 2026-11-10 | Key takeaways
SION filed its 10-Q; the most relevant disclosure change is added Restructuring plan: In September 2026, the board approved a restructuring plan including a 46% workforce reduction following the failure of the PreciSION CF Phase 2a trial for SION-719 as an add-on to Trikafta, with estimated aggregate restructuring charges of $6.4 million and $4.
Key takeaways
Restructuring: Company announced a workforce reduction of approximately 46% in September 2026 following Phase 2a PreciSION CF trial failure for SION-719 as add-on to Trikafta
Restructuring charges: Approximately $6.2 million recognized in Q3 2026, consisting of $5.8 million in cash-related charges and $0.4 million in stock-based compensation; estimated total charges of $6.4 million
Stock option repricing: Board approved repricing of options to purchase 1,495,491 shares from exercise prices exceeding $18.00 to $7.18 per share effective September 17, 2026, with incremental compensation cost of approximately $3.4 million
Cash position: Cash, cash equivalents and marketable securities of $249.8 million as of September 30, 2026, expected to fund operations into second half of 2029
R&D pipeline shift: Company selected SION-451 + SION-2222 dual combination for advancement following Phase 1 trial; AscenSION CF Phase 2 proof-of-concept trial expected to initiate in Q1 2027
Nine-month net loss widened to $89.1 million from $54.8 million year-over-year, primarily due to increased development activities and personnel costs including stock-based compensation
Accrued expenses increased to $13.9 million from $9.7 million at year-end 2025, including approximately $4.1 million in restructuring-related liabilities
Key metrics
Disclosure changes
- Restructuring plan
In September 2026, the board approved a restructuring plan including a 46% workforce reduction following the failure of the PreciSION CF Phase 2a trial for SION-719 as an add-on to Trikafta, with estimated aggregate restructuring charges of $6.4 million and $4.1 million in unpaid liabilities as of September 30, 2026
Significant operational change that will reduce operating expenses and extend cash runway while refocusing on the SION-451 + SION-2222 dual combination program - Restructuring charges
$6.2 million in restructuring and related charges recognized during three and nine months ended September 30, 2026, consisting of $5.8 million cash-related charges and $0.4 million non-cash stock-based compensation
Material charge impacting Q3 results and providing transparency on cost reduction implementation - Stock option repricing
On September 9, 2026, board approved repricing of options to purchase 1,495,491 shares held by 36 employees from exercise prices exceeding $18.00 per share to $7.18 per share, effective September 17, 2026, with incremental stock-based compensation cost of approximately $3.4 million
Retention mechanism for employees following restructuring with associated compensation expense - Restricted stock units granted
Company granted 703,050 RSUs to retained employees in connection with restructuring and retention program, consisting of time-based RSUs vesting after nine months and performance-based RSUs vesting upon achievement of a development milestone; 699,544 RSUs outstanding as of September 30, 2026
Retention incentive for key employees amid restructuring with unrecognized stock-based compensation of $4.8 million - Clinical development pipeline update
Company announced in August 2026 topline results from Phase 1 trial for SION-451 in dual combinations with SION-2222 and SION-109; selected SION-451 + SION-2222 for advancement; PreciSION CF Phase 2a trial for SION-719 failed to meet key activity endpoint with -1.0 mmol/L mean placebo-adjusted sweat chloride change (p=0.7); post hoc analysis identified potential confounding factors; AscenSION CF Phase 2 proof-of-concept trial expected to initiate Q1 2027
Critical pipeline update following Phase 2 failure and selection of lead combination for future development - Accrued expenses
Accrued expenses increased to $13.9 million as of September 30, 2026 from $9.7 million as of December 31, 2025, including approximately $3.6 million in accrued compensation and $0.5 million in accrued research and development related to restructuring
Reflects restructuring-related liabilities and increased R&D activities
Primary source
TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.
Open SEC filingFollow SION in real time
Get material earnings, filing, IR, and earnings-call alerts by email.